Pegvisomant: Difference between revisions
m Robot: Automated text replacement (-{{SIB}} +, -{{EH}} +, -{{EJ}} +, -{{Editor Help}} +, -{{Editor Join}} +) |
|||
Line 1: | Line 1: | ||
{{SI}} | {{SI}} | ||
Line 7: | Line 7: | ||
{{Pituitary and hypothalamic hormones and analogues}} | {{Pituitary and hypothalamic hormones and analogues}} | ||
[[Category:Endocrinology]] | [[Category:Endocrinology]] | ||
{{WikiDoc Help Menu}} | {{WikiDoc Help Menu}} | ||
{{WikiDoc Sources}} | {{WikiDoc Sources}} |
Revision as of 14:52, 20 August 2012
WikiDoc Resources for Pegvisomant |
Articles |
---|
Most recent articles on Pegvisomant Most cited articles on Pegvisomant |
Media |
Powerpoint slides on Pegvisomant |
Evidence Based Medicine |
Clinical Trials |
Ongoing Trials on Pegvisomant at Clinical Trials.gov Clinical Trials on Pegvisomant at Google
|
Guidelines / Policies / Govt |
US National Guidelines Clearinghouse on Pegvisomant
|
Books |
News |
Commentary |
Definitions |
Patient Resources / Community |
Patient resources on Pegvisomant Discussion groups on Pegvisomant Patient Handouts on Pegvisomant Directions to Hospitals Treating Pegvisomant Risk calculators and risk factors for Pegvisomant
|
Healthcare Provider Resources |
Causes & Risk Factors for Pegvisomant |
Continuing Medical Education (CME) |
International |
|
Business |
Experimental / Informatics |
Pegvisomant is a growth hormone receptor antagonist commonly used in the treatment of acromegaly.